Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Rubius Therapeutics Inc (RUBY)

Rubius Therapeutics Inc (RUBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 678,309
  • Shares Outstanding, K 79,801
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,200 K
  • 60-Month Beta 2.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.60
  • Number of Estimates 5
  • High Estimate -0.41
  • Low Estimate -0.68
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -71.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.26 +13.50%
on 01/31/20
9.09 -9.35%
on 02/13/20
+0.19 (+2.36%)
since 01/24/20
3-Month
7.19 +14.60%
on 12/02/19
14.44 -42.94%
on 12/19/19
+0.11 (+1.35%)
since 11/25/19
52-Week
6.96 +18.39%
on 11/15/19
20.04 -58.88%
on 04/05/19
-7.58 (-47.91%)
since 02/25/19

Most Recent Stories

More News
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 8.24 (-3.06%)
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU

BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

BMRN : 91.00 (-2.15%)
FIXX : 15.82 (-7.38%)
RUBY : 8.24 (-3.06%)
SYBX : 2.39 (-6.27%)
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration

JPM : 126.26 (-4.46%)
RUBY : 8.24 (-3.06%)
Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 8.24 (-3.06%)
Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today...

JPM : 126.26 (-4.46%)
RUBY : 8.24 (-3.06%)
Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 8.24 (-3.06%)
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a...

AXLA : 4.54 (-1.30%)
DNLI : 22.08 (-2.69%)
EVLO : 5.06 (-1.56%)
KLDO : 6.72 (-2.89%)
MRNA : 23.76 (+27.81%)
RUBY : 8.24 (-3.06%)
MCRB : 3.36 (-4.55%)
SYRS : 6.28 (-6.13%)
Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 8.24 (-3.06%)
Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently served as Senior Vice President,...

BMY : 62.14 (-2.86%)
AXLA : 4.54 (-1.30%)
DNLI : 22.08 (-2.69%)
EVLO : 5.06 (-1.56%)
KLDO : 6.72 (-2.89%)
MRNA : 23.76 (+27.81%)
RUBY : 8.24 (-3.06%)
MCRB : 3.36 (-4.55%)
SYRS : 6.28 (-6.13%)
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 4.54 (-1.30%)
DNLI : 22.08 (-2.69%)
EVLO : 5.06 (-1.56%)
KLDO : 6.72 (-2.89%)
MRNA : 23.76 (+27.81%)
RUBY : 8.24 (-3.06%)
MCRB : 3.36 (-4.55%)
SYRS : 6.28 (-6.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RUBY with:

Business Summary

Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

2nd Resistance Point 9.03
1st Resistance Point 8.64
Last Price 8.24
1st Support Level 7.98
2nd Support Level 7.71

See More

52-Week High 20.04
Fibonacci 61.8% 15.04
Fibonacci 50% 13.50
Fibonacci 38.2% 11.96
Last Price 8.24
52-Week Low 6.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar